Shots:
- The P-III (KEYNOTE-B15/EV-304) trial assessed 4 cycles of Keytruda (IV) + Padcev (IV), followed by surgery & then Keytruda (IV, 13 cycles) plus Padcev (IV, 5 cycles) vs neoadj. SoC + surgery in cisplatin-eligible MIBC pts (n=808)
- Trial showed that perioperative combination of Keytruda + Padcev significantly improved EFS, OS & pCR rates vs neoadj. CT & surgery
- Merck’s Keytruda is also being assessed in P-III (KEYNOTE-866 & KEYNOTE-992) trials for MIBC, plus the P-III (KEYNOTE-676) trial in combination with BCG for NMIBC
Ref: Merck | Image: Merck | Press Release
Related News: Merck Reveals Topline P-III (MK-8591A-053) Trial Data on Doravirine/Islatravir to Treat HIV-1 Infection
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
